
Volume Fueling Rise in Part D Specialty Derm Drug Spending
Harvard Medical School researchers reported that from 2013 to 2022, prices were higher and rose faster for specialty medications, but that 80% of the increase in spending 'was due to increased prescriptions, not prices.'
Price increases only accounted for 20% of the total growth in Medicare Part D dermatologic drug spending during the study period, lead author Edward L. Kong, PhD, told Medscape Medical News .
Specialty medications — primarily immunomodulators — 'are just very expensive in general,' and are being rapidly adopted by clinicians, which is driving increased spending, said Kong, who is pursuing an MD degree at the Harvard-MIT Health Sciences and Technology program.
Kong and Arash Mostaghimi, MD, MPA, MPH, medical director of the dermatology consult service at Brigham and Women's Hospital, and associate professor, Harvard Medical School, both in Boston, published their findings in JAMA Dermatology on July 16.
They examined some 95 million prescriptions for Medicare beneficiaries, written by almost 25,000 dermatologists and dermatology-focused advanced practice clinicians. Inflation-adjusted spending increased an average of 16% a year, reaching $2.95 billion in 2022. Over the study time period, specialty drug spending increased just under 30% a year, reaching $2.4 billion in 2022. Spending on nonspecialty medications only grew 0.7% annually during the study period.
By 2022, specialty medications accounted for 81% of all dermatology drug spending, having risen from a third of spending in 2013. Even so specialty medications only represented about 3% of all Medicare Part D dermatology prescriptions in 2022.
Four of the specialty drugs were introduced before 2013: adalimumab (Humira), etanercept (Enbrel), ustekinumab (Stelara), and vismodegib (Erivedge). Six came on the market after 2013: apremilast (Otezla), secukinumab (Cosentyx), ixekizumab (Taltz), dupilumab (Dupixent), guselkumab (Tremfya), risankizumab-rzaa (Skyrizi), and sonidegib (Odomzo).
The older medications had higher price growth than the six newer therapies during the study period. Humira, at the high end, had a 12% price increase per year, while Skyrizi, at the low end, had a 5% yearly decrease.
It's possible that biosimilars for Humira and Stelara — introduced in 2023 and this year — might help restrain cost growth, wrote Kong and Mostaghimi. The introduction of generic oral JAK inhibitors such as tofacitinib may also put a dent in spending, they noted.
Medicare will also likely achieve cost savings in 2026 on Enbrel and Stelara, which are included as part of a law — the Inflation Reduction Act— that gave the health program the power to negotiate prices of certain medications. Patients for affordable drugs now estimate that list prices for Enbrel will drop from around $7000 to $2355 and for Stelara from $13,836 to $4695.
The study did not examine the value of the high-cost specialty drugs, but the rise in prescriptions — indicated by each of the 10 achieving a 1% market share — shows that the medications are being embraced, wrote Kong and Mostaghimi.
The authors' work is similar to other studies that have documented major increases in Medicare Part D dermatologic drug spending being driven in part by increased adoption of specialty medications. A 2022 study in the Journal of the American Academy of Dermatology found that from 2013 to 2019, the price of six dermatology drugs in the top 10 most-prescribed medications decreased, mostly among nonspecialty medications. But in 2013, Enbrel was the most expensive medication in the top 50 most prescribed. Enbrel had been replaced in 2019 by Humira.
In 2020, researchers reported in the Journal of Dermatological Treatment that annual spending on immunomodulator medications by Medicare Part D increased 303% from $1.7 billion in 2012 to $6.9 billion in 2018. 'Immunomodulator spending is growing and may be more substantial than previously reported posing significant burden on patients and the health system,' the authors wrote.
Kong and Mostaghimi agreed, writing that 'the growing significance of specialty medications will have important implications for healthcare costs and patient affordability.'
Kong reported receiving grants from the National Institute on Aging. Mostaghimi reported receiving personal fees from Hims & Hers Health, AbbVie, Sun Pharma, Digital Diagnostics, Eli Lilly, Equillium, ASLAN Pharmaceuticals, Boehringer Ingelheim, Figure 1, Indomo, Olaplex, Legacy Healthcare, Pelage, Q32 Bio, Astria Therapeutics, ACOM Health, Bioniz, Concert, and Digital Diagnostics; equity from ACOM Health, Figure 1, and Hims & Hers Health; licensing or royalties from Concert and Pfizer; and research funding from Aclaris, Concert, Eli Lilly, and Incyte outside the submitted work.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
How running for 75 minutes a week could help you live longer — and feel younger
When you buy through links on our articles, Future and its syndication partners may earn a commission. It's no secret that regular exercise is good for your health, but new research has uncovered a fascinating link between running and biological aging. In a study of over 4,400 U.S. adults, researchers found that those who jogged or ran for at least 75 minutes per week had significantly longer leukocyte telomeres. That might sound like something out of a science textbook, but it's really just a fancy way of saying your cells look younger on the inside. Telomeres sit at the ends of your chromosomes and act like little caps that protect your DNA. The longer they are, the better off you tend to be when it comes to aging. If you're looking to get started or find the right shoes for your runs, check out our guide to the best running shoes for every type of runner. This Brooks sneaker offers excellent comfort and support for everyday runs. The 27% saving applies to the women's model, but you'll find the same deal on the men's version as well. Just double-check that your size and favorite color are included in the offer before Deal The magic number is 75 minutes a week The study used data from the National Health and Nutrition Examination Survey and grouped people into three categories based on how much they ran each week. Only those who hit 75 minutes or more saw significant benefits to their telomere length, even after researchers controlled for differences in age, lifestyle, and medical history. In fact, the difference was big enough to suggest runners could be roughly 12 years biologically younger than those who don't run regularly. People who ran less than that? Well, they pretty much looked the same as the non-runners. While the results are compelling, it's worth being cautious. The results come from a single snapshot in time and rely on people accurately reporting their exercise, which can sometimes be optimistic. Still, the message is clear and encouraging: making running a regular habit might just be one of the simplest ways to help your cells stay spry. How to make it work for you The best part is that 75 minutes per week breaks down to just over 10 minutes (and 43 seconds if we are being pernickety) a day. That's a realistic goal for many people. If you're just getting started, try alternating walking and running using a beginner-friendly approach like Jeffing. This run-walk method can help you build endurance while easing the impact on your joints. Our fitness editor Jane swapped running for 'Jeffing' for a week and found it surprisingly enjoyable. And if running isn't your thing, other vigorous activities like swimming, cycling, or cardio workouts could offer similar benefits. Whichever route you choose, the science is stacking up in favor of getting your heart rate up. Follow Tom's Guide on Google News to get our up-to-date news, how-tos, and reviews in your feeds. Make sure to click the Follow button. More from Tom's Guide Forget the sauna — soaking in a hot tub could be better for your health, says new study No, not crunches — trainer says these 5 bodyweight moves are the secret to building stronger abs Fibermaxxing is the latest gut health trend, but does it really work?
Yahoo
2 hours ago
- Yahoo
Astronomer CPO Kristin Cabot Resigns After Attending Coldplay Concert With CEO Andy Byron
Astronomer's Chief People Officer has resigned from her position at the tech company after being caught on video at a Coldplay concert with the then-CEO . "Kristin Cabot is no longer with Astronomer," a spokesperson for Astronomer told Us Weekly on Thursday, July 24. "She has resigned." Cabot's life changed forever after she attended Coldplay's concert at Gillette Stadium in Foxboro, Massachusetts, on July 16. During the show, lead singer Chris Martin took a pause from performing to introduce the venue's kiss cam. The jumbotron showed Astronomer executives Cabot and Byron embracing each other before they quickly tried to dodge the cameras when they realized they were onscreen. Astronomer Cofounder Breaks Silence on Andy Byron and Kristin Cabot's Coldplay Kiss Cam Controversy 'Whoa, look at these two. All right, come on. You're OK,' Martin said as the pair tried to hide their faces and escape the camera. 'Either they're having an affair or they're just very shy. I'm not quite sure what to do.' As the camera panned to other audience members — two individuals dressed in banana costumes — Martin had one final thought about what he had just witnessed during his show. 'Holy s***,' he added. 'I hope we didn't do something bad.' Hours after the concert moment was caught on camera, footage began going viral on social media. The internet did some digging and discovered Andy is reportedly married — to a woman multiple outlets identified as — not Cabot. Since the scandal broke, Megan appeared to remove 'Byron' from her Facebook page, according to a screenshot published by Newsweek. She has also deleted her account. Andy resigned from his position as CEO on July 19. Astronomer cofounder Pete DeJoy is now serving as interim CEO. Stars React After Coldplay Jumbotron Seemingly Exposes Affair Between Astronomer Executives Us Weekly previously reached out to Astronomer and both executives for comment. Since November 2024, Cabot has held the title of Astronomer's Chief People Officer. According to the site's website, the tech company aims to empower data teams to bring mission-critical software, analytics and AI to life. Coldplay Fan Addresses Posting Jumbotron Video of Astronomer Executives: 'Play Stupid Games' 'I prefer to think of my role as people strategy versus traditional human resource,' Cabot said in a press release at the time of her hiring. 'I was energized in my conversations with Andy and the Astronomer leadership team about the opportunities that exist here.' Andy also expressed his excitement at the company's new hire. 'Kristin's exceptional leadership and deep expertise in talent management, employee engagement and scaling people strategies will be critical as we continue our rapid trajectory,' he said. 'She is a proven leader at multiple growth-stage companies and her passion for fostering diverse, collaborative workplaces makes her a perfect fit for Astronomer.' Solve the daily Crossword

Associated Press
2 hours ago
- Associated Press
Colipse Coffee Expands Its Swiss Water® Decaf Line with New Sizes and Grind Options
Chemical-free decaf gets major upgrade with four bag sizes, precision grinds, and bulk savings up to 40% per ounce 'Decaf is no longer just a side option. Our customers want the same richness and complexity they get from regular coffee so we revisited the roast and built a lineup that stands on its own.'— Michal Sieroslawski, founder of Colipse Coffee BOSTON, MA, UNITED STATES, July 27, 2025 / / -- Colipse Coffee, a specialty coffee brand that has seen 200% growth in decaf coffee sales over the past year, today announced a comprehensive expansion of its Swiss Water® Process decaf collection. The upgrade introduces four bag sizes, four grind options, and bulk pricing that saves customers up to 40% per ounce. The decaf market is growing steadily as consumers increasingly prioritize sleep quality, anxiety management, and caffeine control for medical conditions. Pregnant women, medication users, and those with digestive sensitivities are driving demand for high-quality decaf that doesn't sacrifice taste. Unlike traditional chemical methods using methylene chloride or ethyl acetate, Colipse's Swiss Water® process removes 99.9% of caffeine using only water, temperature, and time – making it increasingly valuable to health-conscious consumers. The numbers reflect this shift: the global decaffeinated coffee market reached $2.39 billion in 2024 and is projected to grow at 7.2% annually through 2035, significantly outpacing traditional coffee. The National Coffee Association reports 7% of Americans now consume decaf daily, with strongest growth among health-focused consumers aged 40 and over. Product Expansion Details Bag Sizes: Now offered in 12 oz, 16 oz, 2 lb, and 5 lb formats for all Colipse Swiss Water decaf coffees Grind Options: Available as whole bean, coarse (for French press & cold brew), medium (for drip), and fine (for espresso & moka) Bulk Savings: Customers can save up to 40% per ounce with larger 5 lb bags Flexible Subscriptions: Choose grind type, bag size, delivery schedule, and pause or skip anytime The expanded line works seamlessly with popular equipment including Jura, De'Longhi, Breville, and Gaggia machines, plus manual methods like Chemex, Hario V60, and French press. Each order is roasted fresh, vacuum-sealed for peak flavor retention, and ships free across the United States. The expanded Swiss Water® decaf line is available immediately at with introductory pricing starting at $21.95 for 12 oz bags. Bulk discounts apply automatically, and subscription customers receive an additional 5% off all orders. 'I was looking for the cleanest and best decaf coffee on the market and I think I found it,' said Charlotte Anderson, a Colipse customer. 'This coffee is delicious - my stomach can't handle caffeine, but I don't have to sacrifice taste.' About Colipse Coffee Founded in 2024, Colipse Coffee is a New Mexico-based specialty coffee company committed to delivering exceptional coffee through sustainable practices and innovative processing methods. The company has experienced rapid growth by focusing on quality, freshness, and customer service. Michal Sieroslawski Colipse Coffee +1 505-445-3781 email us here Visit us on social media: LinkedIn Facebook X Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.